Arvin Biopharma LTD marketing director Ali Bamdad said about the appeal of the Russian drug, and offered details about the economics and investment requirements for the project.
Bamdad noted that "a whole range of factors" was at play. "For starters, the economic relations between Iran and Russia are very actively being developed and strengthened at present. We had offers from our Ministry of Health and other government agencies on more active cooperation with Russia," Sputnik cited him as saying.
At the same time, he noted that the Russian-made vaccine`s innovative nature was a significant factor, too. "The Russian drug is unique; we have not yet met with analogues to it… today, Grippol Plus is the most innovative and unique product [in its category]."
More about:
